AOD-9604
Advanced Obesity Drug (HGH Fragment 176-191)
The HGH fragment that targets fat without the side effects
AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates fat metabolism without affecting blood sugar or growth. Originally developed as an anti-obesity drug.
Admin routes
Subcutaneous, Oral
Popularity
Medium
Side effects
Generally mild
AU vendors
4 rated
✓Key benefits
📈What to expect
Subtle metabolic changes; no dramatic initial effects
Beginning of fat mobilisation; improved energy
Measurable reduction in stubborn fat areas
Cumulative fat loss; best results with exercise
Based on community reports and published research. Individual results vary significantly.
💊Dosing protocols
Fat loss
250–300 mcg
Once daily (fasted, subcutaneous)
12 weeks
Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.
Research status|Phase 2 clinical data - TGA listed in Australia
Overview
AOD-9604 is a synthetic peptide consisting of a modified fragment of human growth hormone - specifically amino acids 176-191 with a tyrosine addition. Developed by Monash University in Melbourne, Australia, it was designed to isolate the fat-burning properties of HGH without its growth-promoting or diabetogenic effects. It completed Phase 2 clinical trials for obesity before development was discontinued due to modest efficacy. However, it has found a second life in the peptide community as a targeted fat loss agent and has been approved by the TGA in Australia for use in certain complementary medicine products.
⚙️How it works
AOD-9604 mimics the lipolytic (fat-burning) region of growth hormone. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) without binding to the growth hormone receptor. This means it does not affect blood sugar, does not promote growth of bone or organs, and does not affect IGF-1 levels. It appears to work by stimulating beta-3 adrenergic receptors on fat cells. The fact that it doesn't trigger the typical HGH side effects (insulin resistance, water retention, joint pain) is its primary appeal.
⚡Side effects
📅Research history
Fragment 176-191 of human growth hormone identified
Clinical trials in Australia for obesity treatment
FDA classifies AOD-9604 as GRAS for food use
Adopted in peptide community for targeted fat loss
Used in combination protocols with GLP-1 agonists
🏪Rated vendors (Australia)
View all →Peptides Collective
Perth, WA · 99%+ (third-party verified) purity · 1–2 days (Perth), 2–4 days (national)
peptidescollective.health ↗LotusLabs
Australia · 99%+ (HPLC and mass spectrometry) purity · Same-day dispatch, 2–3 days delivery
lotuslabs.com.au ↗PeptideConnect
Australia · 99%+ (Janoshik verified) purity · 1–2 days (most capitals)
peptideconnect.com.au ↗The Peptide Co
Australia (multiple depots) · 99%+ (in-house QC) purity · Same-day dispatch, 1–3 days delivery
thepeptideco.com ↗Vendor ratings are based on community feedback and are not endorsements. Always verify third-party certificates of analysis (CoA) and check current Australian regulations before purchasing.
The Australian connection
AOD-9604 is one of the few peptides with a distinctly Australian origin story. It was developed by Professor Frank Ng at Monash University in Melbourne, with the goal of creating a fat-loss compound from HGH that wouldn't trigger growth or insulin resistance. Metabolic Pharmaceuticals Ltd (Melbourne) took it through Phase 2 clinical trials. While the trials showed the compound was safe and produced statistically significant fat loss, the effect size was considered too modest for pharmaceutical registration. Despite this, the TGA approved it for inclusion in complementary medicine products, making it one of the more accessible peptides in Australia.
References
- [1]Heffernan MA, et al. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism." Endocrinology, 2001.
- [2]Stier H, et al. "Safety and tolerability of the hexadecapeptide AOD9604 in humans." Journal of Endocrinology & Metabolism, 2013.
Frequently asked questions
Related peptides
Need to calculate your dose?
Use our free reconstitution calculator to work out syringe units for AOD-9604.
Open CalculatorDisclaimer: This guide is for educational and informational purposes only. It is not medical advice. The dosing protocols listed are sourced from published research and community reports and do not constitute a recommendation. Always consult a qualified healthcare professional before using any peptide. Australian regulations classify many peptides as Schedule 4 (prescription-only) substances. Check current TGA guidelines before purchasing.